E-Mail
IMAGE: The AstroPath platform allows for the assessment of the level of expression of a given marker on individual cells, while maintaining information on their spatial location. Shown here is. view more
Credit: Seyoun Park, Ph.D.
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respond to specific therapies targeting the immune system.
A new platform, called AstroPath, melds astronomic image analysis and mapping with pathology specimens to analyze microscopic images of tumors.
Bristol Myers details data for closely watched cancer immunotherapy biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
email article
A dual immunotherapy regimen targeting the novel lymphocyte-activation gene 3 (LAG-3) immune checkpoint led to a significant progression-free survival (PFS) benefit in patients with advanced melanoma, according to a phase III study.
At a median follow-up of 13.2 months, the combination of the anti-LAG-3 antibody relatlimab and the PD-1 inhibitor nivolumab (Opdivo) extended PFS to 10.1 months, as compared with 4.6 months with nivolumab alone (HR 0.75, 95% CI 0.6-0.9,
P=0.0055), reported Evan Lipson, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. Relatlimab and nivolumab is a potential novel treatment option for this patient population, said Lipson during a press briefing held in advance of the virtual American Society of Clinical Oncology (ASCO) annual meeting.